On June 2, 2025, Escugen's ESG401 (Trop2 ADC) was first reported at the 2025 ASCO meeting in the form of a poster, presenting the clinical trial data of ESG401 in salivary gland cancer.

On June 2, 2025, Escugen presented the latest data from the Phase I clinical trial of ESG401 (Trop2 ADC) in advanced solid tumors at the 2025 ASCO meeting in the form of a poster.